Zanubrutinib, another second-generation irreversible BTK inhibitor that is approved for R/R MZL patients, reduced Treg percent and CTLA-4 expression on Tregs in R/R CLL patients (111). The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.